Back to search

National and Kapodistrian University of Athens

Μελέτη του ρόλου του αυξητικού παράγοντα διαφοροποίησης-15 (GDF-15) στην ηπατική φλεγμονή και ίνωση στην δρεπανοκυτταρική νόσο

Abstract

dc:description

Background: Sickle cell disease (SCD) is one of the most common monogenic disorders, characterized by systemic manifestations and an increased risk of hepatic complications. Liver fibrosis is among the most severe manifestations, contributing to both morbidity and mortality in affected patients. Growth Differentiation Factor-15 (GDF-15) has emerged as a potential biomarker of inflammation and fibrosis in various systemic diseases. Aims: The aim of this study was to assess the prevalence of significant liver fibrosis (≥F2) in adult patients with SCD in Greece and to investigate the associated factors. A secondary objective was to correlate GDF-15 levels with demographic, clinical, and laboratory characteristics, as well as markers of inflammation and fibrosis. Methods: A total of 214 adult patients with SCD (132 females, 82 males) from eight Thalassemia and Sickle Cell Disease Centers across Greece were included in the study. Demographic data, anthropometric measurements, clinical characteristics, imaging parameters, and blood samples for laboratory analyses were collected. Liver fibrosis was assessed using liver elastography, ultrasound and non-invasive indices (APRI and FIB-4). GDF-15 levels were measured in 30 SCD patients using the ELISA method. Results: Significant liver fibrosis (≥F2) was detected in 16.67% of the study patients. In multivariate analysis, significant liver fibrosis was independently associated with age (OR 1.07, p=0.012), liver-related sickle cell crises (OR 3.05, p=0.047), and LDH levels (OR 1.007, p<0.001). GDF-15 levels were significantly higher in patients with fibrosis ≥F2 compared to those without fibrosis (4939.5 vs. 2682 pg/mL, p=0.001). In linear regression analysis, GDF-15 levels were independently associated only with liver elastography values (β=0.619, p=0.002). The area under the curve (AUC) for detecting significant fibrosis using GDF-15 as a diagnostic marker was 0.835 (95% CI: 0.686–0.983, p=0.002). A GDF-15 cutoff of 4200 pg/mL yielded a positive predictive value of 81.8%, negative predictive value of 73.6%, sensitivity of 64.3%, and specificity of 87.5% for the detection of significant liver fibrosis. Conclusion: Significant liver fibrosis is common among Greek patients with SCD. GDF-15 appears to be a potential non-invasive marker of liver fibrosis and may contribute to its early detection in patients with SCD.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Manganas, Konstantinos
  • Μαγγανάς, Κωνσταντίνος

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/61550

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Manganas, Konstantinos; Μαγγανάς, Κωνσταντίνος. Μελέτη του ρόλου του αυξητικού παράγοντα διαφοροποίησης-15 (GDF-15) στην ηπατική φλεγμονή και ίνωση στην δρεπανοκυτταρική νόσο. National and Kapodistrian University of Athens, 2026. http://hdl.handle.net/10442/hedi/61550